Bioproduction

Global Bioproduction Market to Reach US$61.6 Billion by 2030

The global market for Bioproduction estimated at US$28.1 Billion in the year 2024, is expected to reach US$61.6 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Biologics & Biosimilars, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$32.6 Billion by the end of the analysis period. Growth in the Vaccines segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.7 Billion While China is Forecast to Grow at 19.0% CAGR

The Bioproduction market in the U.S. is estimated at US$7.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.4 Billion by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global Bioproduction Market – Key Trends & Drivers Summarized

Why Is Bioproduction Gaining Strategic Importance in the Future of Industrial and Therapeutic Manufacturing?

Bioproduction is rapidly emerging as a critical enabler of modern industrial and biopharmaceutical manufacturing, offering a biologically-driven alternative to traditional synthetic production methods. It refers to the use of living organisms—such as bacteria, yeast, algae, or mammalian cells—to produce a wide range of products, including therapeutic proteins, enzymes, biofuels, vaccines, monoclonal antibodies, and specialty chemicals. As the global demand for biologics, sustainable materials, and eco-friendly manufacturing practices rises, bioproduction is positioned as a highly scalable and sustainable solution that aligns with the needs of the 21st-century economy. In the pharmaceutical sector, bioproduction is indispensable for developing complex biologics that cannot be synthesized chemically, such as insulin, erythropoietin, and various cell and gene therapies. Outside pharma, bioproduction plays a key role in producing biodegradable plastics, plant-based meat alternatives, and bio-based ingredients in the cosmetics, food, and agriculture industries. Its ability to produce high-purity, high-potency substances using renewable feedstocks makes it an attractive alternative to petroleum-based manufacturing. Moreover, bioproduction supports circular economy models, reduces waste, and lowers greenhouse gas emissions, making it a priority in global decarbonization strategies. With its convergence of biology, engineering, and data science, bioproduction is no longer just a research niche—it’s an industrial revolution in motion, shaping how we create, consume, and conserve resources across industries.

How Are Emerging Technologies and Tools Advancing the Scope and Efficiency of Bioproduction?

Technological innovation is driving the next wave of efficiency, scalability, and customization in bioproduction systems. Key breakthroughs in synthetic biology and metabolic engineering are allowing scientists to program microorganisms with precision, optimizing biosynthetic pathways to maximize yield and minimize by-product formation. CRISPR-Cas and other genome-editing tools are enabling highly targeted genetic modifications, accelerating strain development and enhancing product consistency. Continuous bioprocessing and modular bioproduction platforms are replacing traditional batch processes, offering reduced downtime, higher throughput, and better scalability. Advanced bioreactor designs—including single-use systems, perfusion reactors, and microfluidic platforms—are improving flexibility and enabling real-time adjustments during production. Meanwhile, AI and machine learning algorithms are being employed to predict cell behavior, optimize fermentation parameters, and detect anomalies across upstream and downstream operations. Integration with IoT devices and process analytical technology (PAT) is further enhancing monitoring capabilities, allowing real-time data acquisition and dynamic process control. Furthermore, advancements in downstream processing—such as high-resolution chromatography, membrane filtration, and precipitation technologies—are improving product recovery and purity, especially in high-value therapeutic applications. Cell-free bioproduction systems are also gaining attention for their ability to bypass the limitations of living systems, enabling faster prototyping and on-demand synthesis. As digitalization, automation, and biological sciences continue to converge, the bioproduction industry is evolving into a smart, adaptive, and data-driven ecosystem capable of meeting diverse product demands while ensuring regulatory compliance and process robustness.

Which Industries and Geographies Are Driving the Expansion of the Global Bioproduction Ecosystem?

Bioproduction is experiencing accelerated adoption across a broad spectrum of industries and regions, each leveraging biological manufacturing to achieve strategic, regulatory, or sustainability goals. The pharmaceutical and biotechnology sectors remain the largest consumers of bioproduction systems, especially for the production of monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies. The food and beverage industry is increasingly adopting bioproduction techniques to create alternative proteins, fermented functional ingredients, and bioactive compounds used in supplements and nutraceuticals. In the energy sector, companies are using engineered microbes to convert biomass into renewable fuels like ethanol, biodiesel, and hydrogen. The cosmetics and personal care sectors are also embracing bioproduction to develop eco-friendly fragrances, colorants, and emulsifiers. Regionally, North America leads the market, driven by robust R&D infrastructure, a high concentration of biotech firms, and favorable regulatory frameworks that support innovation. Europe follows closely, with countries like Germany, Switzerland, and the Netherlands focusing on bioeconomy strategies, sustainable chemistry, and green manufacturing. Asia-Pacific is the fastest-growing region, with rapid industrialization, growing investment in life sciences, and supportive government initiatives in countries such as China, India, Japan, and South Korea. Latin America and Africa, while still emerging, are beginning to tap into bioproduction potential by leveraging local biodiversity and agricultural waste streams. In all these regions, public-private partnerships, international research collaborations, and rising consumer demand for sustainable products are fueling the bioproduction market. Whether in therapeutic, industrial, or environmental applications, bioproduction is becoming a global movement that cuts across traditional industry lines and national boundaries.

What Is Fueling the Growth in the Global Bioproduction Market?

The growth in the global bioproduction market is driven by a dynamic combination of scientific innovation, commercial demand, regulatory momentum, and global sustainability goals. One of the most significant growth drivers is the escalating demand for biologics and advanced therapies, particularly in the treatment of chronic, genetic, and rare diseases. These therapies often require highly specialized production systems that only bioproduction platforms can offer. Simultaneously, consumer preferences are shifting toward sustainable, ethically produced, and bio-based products in sectors ranging from personal care to agriculture—prompting companies to invest in bioproduction technologies that align with ESG criteria. Governments and regulatory agencies are also playing a pivotal role by supporting bioproduction through funding, tax incentives, and streamlined approval processes for bio-based innovations. As countries pursue climate action targets and circular economy models, bioproduction stands out for its ability to reduce reliance on petrochemicals, minimize waste, and produce energy and materials in a more environmentally friendly way. Additionally, the scalability and flexibility of modern bioproduction systems make them suitable for both large-scale industrial applications and localized, on-demand production—providing resilience and adaptability in volatile supply chain environments. The growth of CDMOs and biofoundries is further accelerating market development by offering outsourced, cost-effective access to high-end bioproduction capabilities. Together, these factors are not only fueling rapid expansion but are also setting the stage for bioproduction to become a foundational technology in a bio-based global economy—reshaping the future of how goods and medicines are produced, consumed, and sustained.

SCOPE OF STUDY:

The report analyzes the Bioproduction market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Biologics & Biosimilars, Vaccines, Cell & Gene Therapies, Nucleic Acid Therapeutics); Application (Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application, Cardiovascular Diseases Application); End-Use (BioPharmaceuticals Companies End-Use, Contract Manufacturing Organizations End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AGC Biologics
• Ajinomoto Bio-Pharma Services
• BioVectra
• Boehringer Ingelheim BioXcellence
• Catalent, Inc.
• Charles River Laboratories
• Cytiva
• Emergent BioSolutions
• FUJIFILM Diosynth Biotechnologies
• Genscript Biotech
• KBI Biopharma
• Lonza Group
• MilliporeSigma (Merck KGaA)
• Novartis
• Pfizer CentreOne
• Resilience (National Resilience, Inc.)
• Rentschler Biopharma SE
• Samsung Biologics
• Sartorius AG
• WuXi Biologics

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more